NasdaqGM:XOMA 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	6	-45	28	0
31 Dec 23	5	-46	26	0
30 Sep 23	4	-32	26	0
30 Jun 23	4	-31	24	0
31 Mar 23	3	-30	24	0
31 Dec 22	6	-23	23	0
30 Sep 22	40	10	21	0
30 Jun 22	41	10	21	0
31 Mar 22	41	12	19	0
31 Dec 21	38	8	20	0
30 Sep 21	30	1	19	0
30 Jun 21	29	6	18	0
31 Mar 21	29	6	17	0
31 Dec 20	29	9	17	0
30 Sep 20	2	-13	17	0
30 Jun 20	11	-9	20	0
31 Mar 20	11	-10	21	0
31 Dec 19	18	-2	21	0
30 Sep 19	20	-2	21	0
30 Jun 19	12	-8	20	0
31 Mar 19	13	-6	19	0
31 Dec 18	5	-13	19	0
30 Sep 18	9	-11	21	0
30 Jun 18	44	9	24	0
31 Mar 18	53	18	24	0
31 Dec 17	53	6	24	0
30 Sep 17	48	-11	23	43
30 Jun 17	12	-39	20	43
31 Mar 17	2	-61	19	43
31 Dec 16	6	-54	18	43
30 Sep 16	53	-11	19	11
30 Jun 16	55	1	20	23
31 Mar 16	57	-7	20	37
31 Dec 15	55	-21	21	50
30 Sep 15	12	-53	20	52
30 Jun 15	15	-67	20	53
31 Mar 15	18	-55	20	50
31 Dec 14	19	-38	20	51
30 Sep 14	27	-83	21	86
30 Jun 14	28	-99	21	54
31 Mar 14	29	-104	20	62
31 Dec 13	35	-124	18	47
30 Sep 13	30	-69	17	7
30 Jun 13	31	-67	17	35

質の高い収益: XOMAは現在利益が出ていません。

利益率の向上: XOMAは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: XOMAは利益が出ておらず、過去 5 年間で損失は年間43%の割合で増加しています。

成長の加速: XOMAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: XOMAは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: XOMAは現在利益が出ていないため、自己資本利益率 ( -48.11% ) はマイナスです。

XOMA 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

Consensus revenue estimates increase by 64%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 58%

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 33%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Price target increased to US$62.50

Consensus revenue estimates fall by 65%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Investor sentiment deteriorated over the past week

CEO & Chairman of the Board exercised options and sold US$645k worth of stock

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

Investor sentiment improved over the past week

Consensus revenue estimates fall by 14%

Consensus revenue estimates increase by 12%

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$62.50

Now 24% undervalued

XOMA Corporation, Annual General Meeting, May 18, 2022

Investor sentiment improved over the past week

Now 20% undervalued

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment improved over the past week

Price target increased to US$49.00

Price target decreased to US$46.00

Investor sentiment deteriorated over the past week

Xoma Gets The Spotlight

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall to US$9.98m

Consensus EPS estimates increase to -US$0.83

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

Price target increased to US$52.33

CEO & Director recently sold US$303k worth of stock

Investor sentiment improved over the past week

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

Consensus EPS estimates fall to -US$1.00

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

XOMA EPS misses by $0.55, misses on revenue

XOMA gets milestone payment from Janssen Biotech

Investor sentiment improved over the past week

Key Executive exercised options to buy US$212k worth of stock.

XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Consensus revenue estimates increase to US$17.1m

過去基準チェック /06